Rain Therapeutics Inc. (RAIN) Social Stream
RAIN ONCOLOGY INC (RAIN) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering RAIN.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-08-10 | 3 | $28 | $25 | $26.333 | $0.822 | 3103.53% |
| 2022-03-03 | 3 | $28 | $26 | $26.666 | $0.822 | 3144.04% |
| 2022-05-04 | 4 | $28 | $15 | $23.75 | $0.822 | 2789.29% |
| 2022-05-05 | 4 | $28 | $16 | $24 | $0.822 | 2819.71% |
| 2022-05-27 | 2 | $16 | $12 | $14 | $0.822 | 1603.16% |
| 2022-08-05 | 3 | $16 | $12 | $14.666 | $0.822 | 1684.18% |
| 2022-11-11 | 4 | $16 | $10 | $13.5 | $0.822 | 1542.34% |
| 2022-11-23 | 5 | $29 | $12 | $17 | $0.822 | 1968.13% |
| 2023-01-05 | 7 | $29 | $12 | $16.833 | $0.822 | 1947.81% |
| 2023-01-06 | 6 | $29 | $12 | $17 | $0.822 | 1968.13% |
| 2023-01-20 | 6 | $29 | $12 | $17.5 | $0.822 | 2028.95% |
| 2023-01-23 | 7 | $29 | $12 | $17.5 | $0.822 | 2028.95% |
| 2023-03-10 | 8 | $29 | $12 | $18 | $0.822 | 2089.78% |
| 2023-03-13 | 8 | $29 | $15 | $18.75 | $0.822 | 2181.02% |
| 2023-05-15 | 9 | $24 | $11 | $17.333 | $0.822 | 2008.64% |
| 2023-05-23 | 9 | $17 | $1.5 | $9.156 | $0.822 | 1013.87% |
| 2023-05-30 | 10 | $17 | $1.5 | $6.607 | $0.822 | 703.77% |
| 2023-05-31 | 10 | $17 | $1.2 | $6.492 | $0.822 | 689.78% |
| 2023-08-10 | 9 | $17 | $1 | $4.208 | $0.822 | 411.92% |
The Trend in the Analyst Price Target
RAIN's average price target has moved down $21.47 over the prior 23 months.
RAIN reports an average of 185.19% for its upside potential over the past 41 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-05 | 7 | 29 | 12 | 16.833 | 8.66 | 94.38% |
| 2023-01-23 | 8 | 29 | 12 | 17.500 | 9.85 | 77.66% |
| 2023-02-09 | 8 | 29 | 12 | 18.000 | 9.00 | 100% |
| 2023-03-10 | 8 | 29 | 12 | 18.000 | 8.99 | 100.22% |
| 2023-05-15 | 9 | 24 | 11 | 17.333 | 9.58 | 80.93% |
RAIN Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 3 | 0 | 0 | 9 | 0 | 0 | 9 |
The Trend in the Broker Recommendations
RAIN's average broker recommendation rating worsened by 2 over the prior 17 months.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In the context of all US stocks, RAIN ONCOLOGY INC's upside potential (average analyst target price relative to current price) is higher than 3034.5% of them.
- To contextualize these metrics, consider that out of all US stocks, RAIN ONCOLOGY INC's variance in analysts' estimates is lower than -2020.14% of them.
- In the context of stocks in the small market cap category, RAIN ONCOLOGY INC's number of analysts covering the stock is higher than 2034.32% of them.
- RAIN ONCOLOGY INC's average analyst price target is greater than 886.88% of Healthcare stocks.
Stocks similar to RAIN ONCOLOGY INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are HOWL, VACC, and VERA.
View All Top Stocks by Price Target
What is the outlook for RAIN? Use POWR Ratings for clearer insight into price direction.